About us

A mission with
a long memory.

The people, experience and partnerships behind the next chapter.

Founders’ journey

Experience carried
into a new generation.

MondoBiotech.
The starting point.

MondoBiotech’s mission was to connect scientific knowledge with diseases that had too few development paths. The founders’ scientific work, business experience and lessons learned form the context for the new chapter.

MondoTwin brings that context together with Francesco’s technical generation: ontology, agents and a shared company operating foundation.

  1. 2002

    InterMune

    Research collaboration on interferon gamma-1b in pulmonary diseases, including asthma, covering patent rights in idiopathic pulmonary fibrosis.

    BioWorld, 11 Apr 2002

  2. 2006

    Biogen Idec

    Licence to develop aviptadil in pulmonary arterial hypertension: USD 7.5 million upfront and up to USD 30 million in milestones.

    What followed. Biogen ended its participation in the programme in December 2009.

    Fierce Biotech, 13 Sep 2006Biogen Idec, Form 10-K 2009

  3. 2009

    Bachem

    Long-term agreement for Bachem to develop and manufacture the peptides of MondoBiotech’s programmes.

    Dow Jones Newswires, 24 Sep 2009

  4. 2009

    SIX Swiss Exchange

    Shares listed on 26 August 2009 under the symbol RARE.

    SIX Swiss Exchange

  5. 2010

    Lung Rx, a United Therapeutics company

    Partnership for the further development of aviptadil.

    What followed. The aviptadil patents passed to Relief Therapeutics in 2016; in 2020 the FDA granted aviptadil fast-track designation for respiratory distress in COVID-19.

    AWP, 4 Feb 2010Wikipedia, Relief Therapeutics

  6. 2013

    Pierrel Research International

    MondoBiotech is renamed THERAMetrics and combines with Pierrel Research.

    What followed. In 2016 the company became Relief Therapeutics Holding AG.

    THERAMetrics, Annual Report 2013Relief Therapeutics, 18 Jul 2016

  7. Prizes

    Swiss Life Sciences Prize, 2005Ernst & Young Entrepreneur of the Year, Switzerland, start-up category, 2006World Economic Forum Technology Pioneer, 2008

  8. 2026

    MondoTwin is founded to run the same model with AI, across the public clinical evidence.

MondoBiotech and SHRARE Technology AG are separate companies. The record follows the Wikipedia article on Mondobiotech and the sources it cites.

Mission & vision

Medicines from evidence.
A twin beside every department.

Drugs already proven in humans hold new medicines: new indications, combinations, forms, and approved products never launched in half the world. Finding and assembling them is still done by hand. We are building the company that does it with agents, and the same way of working serves every company that runs on evidence.

  1. Mission

    Turn the evidence that already exists into medicines.

    We read the public clinical evidence as one body, find the assets with human data behind them, secure them with our community and bring them to pharma de-risked, ready for signature.

  2. How we build it

    De-risked assets, at scale, with a community.

    Human evidence first. Breadth no team can reach by hand. Researchers, rights holders and specialists who carry each asset forward. An ontology that learns from every task, and agents that do the work.

  3. Vision

    A twin beside every department.

    In our experience, transforming an existing department with AI takes longer than planned. An AI-native twin built beside it, with the people who know the work, delivers sooner, and the company integrates it at its own pace. Written as procedures and rules, each twin makes the next one faster to build.

MondoTEAM & partners

Expertise connected
around the work.

An entrepreneurial, scientific and technical foundation, extended through specialist partnerships.

Francesco Cavalli

Founder and Chief Executive Officer

LinkedIn

Francesco Cavalli holds a BSc in Computational Science and Engineering from ETH Zurich and is a researcher at the ETH Agentic Systems Lab, working on agentic AI for regulatory affairs, with a background in high-performance computing and machine learning. He is the architect of the MondoTwin ontology, its learning pipeline and the agents that run the company. He has published at PASC 2024 and in Frontiers in Nutrition.

Nicola Lo Russo

AI Engineer

LinkedIn

Nicola Lo Russo holds an MSc from ETH Zurich. He builds the MondoTwin platform, from the analysts’ interface to security and identity. He was previously a software engineer at DSwiss, the Swiss provider of SecureSafe, and is co-author with Francesco Cavalli at PASC 2024.

Marie Louise Gloria

AI-native Twin operator · Client relations & communications

Marie Louise Gloria is an AI-native Twin operator. She works with clients to understand what they need, then creates and operates the AI-native twins MondoTwin builds for them, so that each one works well in the client’s hands. She also leads customer relationships and communications.

Dr Robert Jakob

Member of the Advisory Board

LinkedIn

Robert Jakob is founder and co-director of the Agentic Systems Lab at ETH Zurich and holds a PhD in applied machine learning from ETH Zurich. He is co-creator of OpenTSLM, open time-series language models for medicine developed with Stanford and Google Research. He was previously at Harvard’s Statistical Reinforcement Learning Lab, the Singapore-ETH Centre and Dartmouth, and publishes at ICLR, ICML, AAAI and CHI.

Hans-Peter Hasler

Member of the Advisory Board

LinkedIn

Hans-Peter Hasler is Chairman of the Board of HBM Healthcare Investments AG, listed on the SIX Swiss Exchange. He was Chief Operating Officer of Biogen and head of its global neurology business, Chief Operating Officer of Elan Corporation and a senior executive at Wyeth Pharmaceuticals. He has chaired and served on the boards of Shield Therapeutics, Minerva Neurosciences and Gain Therapeutics.

Prof. Giovanni Landoni, MD

Member of the Advisory Board, Medical

LinkedIn

Giovanni Landoni is Full Professor of Anaesthesia and Intensive Care at Vita-Salute San Raffaele University, Milan, and Director of the Center for Intensive Care and Anesthesiology at the San Raffaele Scientific Institute. He is the author of more than six hundred indexed publications, including randomised trials in The New England Journal of Medicine, The Lancet and JAMA.

Dr Gianpaolo Turri

Member of the Advisory Board

LinkedIn

Gianpaolo Turri was Chief Executive Officer of Infranor Holding, a global robotics and industrial automation group, and before that President of the Adamant Namiki group’s business in Europe and the United States. He holds a PhD in physics from Imperial College London and was a Marie Curie fellow, with research at UCLA, the Max Planck Institute and EPFL.

Daniele Ruaro

Member of the Advisory Board

Daniele Ruaro is co-founder and Chief Commercial Officer of BAI Technologies, a Swiss healthcare technology company, and founder and Chief Executive Officer of Organoids International in Dubai. He has commercialised ventures in healthcare, biotechnology and sustainability for more than seventeen years and holds an MSc from the University of Milano-Bicocca.

Dr Hans-Lothar Arth

Member of the Advisory Board, Intellectual Property

LinkedIn

Hans-Lothar Arth is a European and German patent attorney and holds a PhD in chemistry. He is the founder of ABK Patent, Trademark and Design Attorneys and built the intellectual property department of Axxima Pharmaceuticals.

Dr Mattia Albergante

Member of the Advisory Board, Technology

LinkedIn

Mattia Albergante is Chief Technology Officer of Axmed, the marketplace for affordable medicines in low- and middle-income countries backed by the Gates Foundation. He spent nine years at Frontiers, the open-access scientific publisher, where he founded its data and AI unit, led the AI behind its review assistant AIRA and became Director of Product Management. He holds a PhD in physics from EPFL.

Dr Kevin O’Sullivan

Member of the Advisory Board

LinkedIn

Kevin O’Sullivan is founder and co-director of the Agentic Systems Lab and a lecturer at ETH Zurich. He holds a PhD from ETH Zurich’s Bits to Energy Lab on digital health interventions, including a randomised clinical trial, and a master’s degree in biomedical engineering from Trinity College Dublin. He was previously a software engineer in financial and educational technology and an engineer in the semiconductor industry.

Fabio Cavalli

Member of the Board of Directors

LinkedIn

Fabio Cavalli founded Mondobiotech in 2000, an early practitioner of the search-and-license model in rare diseases. Under his leadership the company licensed programmes to InterMune in 2002, to Biogen Idec in 2006 and to Lung Rx, a United Therapeutics company, in 2010, and listed on the SIX Swiss Exchange in 2009. He works full time for MondoTwin.

Careers

Engineers, scientists and business developers,
in Basel and Zurich.

MondoTwin recruits people who combine rigour with execution and are at ease working across science, systems and strategy. Applications are considered on an ongoing basis; please write to us with a curriculum vitae and a short note on the work you would like to do.

  1. Engineering

    Engineers in machine learning, data systems, language-model workflows and multi-agent architectures, building the platform and the pipeline that runs the department.

  2. Science and development

    Professionals in drug development, translational medicine, clinical development, regulatory strategy and scientific evaluation, with experience in rare diseases.

  3. Business development

    Professionals with a record in pharmaceutical licensing, search and evaluation, and transaction support, who work with clients from the mandate to the signature.

Contact

Pharmaceutical companies, researchers and institutions, candidates and the press reach us here.

Your message is read and answered personally.

We use your details to answer you. Your rights in anything you send stay with you. See the Privacy Policy.